• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Endari reduces pain crises, hospitalizations in sickle cell patients, phase 3 trial shows


Treatment with Endari (L-glutamine) leads to fewer pain crises and hospitalizations in patients with sickle cell disease, according to final results of a Phase 3 clinical trial.

These results were published in the study, “A Phase 3 Trial of l-Glutamine in Sickle Cell Disease,” in the New England Journal of Medicine.

Patients with sickle cell disease have increased levels of oxidative stress, which has been shown to contribute to the development of the disease. Oxidative stress occurs when the amount of oxygen-related toxic molecules exceeds the natural levels of counteracting antioxidants, leading to cellular damage.



To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.